Page 163 - FINAL PROGRAM

Male and female fertility preservation
P-472 Prospective, multicentric study of AMH decay during chemotherapy for breast cancer treatment in 134 young women of reproductive age
P. Barriere (France)
P-473 Ovarian response to controlled ovarian stimulation for fertility preservation before oncology treatment: A retrospective cohort of 128 patients
N. Tsampras (United Kingdom)
P-474 Highly sensitive assessment of neuroblastoma minimal residual disease in testicular tissue using RT-qPCR – A strategy for improving the safety of fertility restoration
F. Brugnon (France)
P-475 Male fertility preservation outside reprotoxicant treatments: indications, use rate and ART outcome in 1,966 patients
J. Perrin (France)
P-476 Telomerase length in granulosa cells and lymphocytes of women recently diagnosed with cancer
M. Martinez (Spain)
P-477 Transport and handling of oocytes after vitri cation in a closed vitri cation system (Rapid-i): Proposal for and implementation of a standard validation procedure
A. Rayss (Germany)
P-478 Time between exposure to rst line of chemotherapy and oocyte retrieval for fertility preservation: cytotoxicity and genotoxicity assay of cytarabin and daunorubicin on mouse ovaries
E. Balenbois (France)
P-479 Immature oocyte retrieval followed by in vitro maturation (IVM) and vitri cation in combination with laparascopic ovarian tissue cryopreservation (OTCP) for fertility preservation: UK pilot study
C. Ross (United Kingdom)
P-480 Oncofertility: Optimum transport conditions for ovarian tissue cryopreservation prior freezing
R. Dittrich (Germany)
P-481 Fertility preservation public program. Is it worthwhile?
A.B. Rodriguez Bujez (Spain)
P-482 Topical high concentration of anti-Müllerian hormone prevents follicle activation and loss caused by chemotherapy in vivo
S. Tan (Taiwan R.O.C.)
FINAL PROGRAMME I HELSINKI, FINLAND – 3 TO 6 JULY 2016 159
POSTERS